Clinical trial
Combination Chemotherapy With or Without Trastuzumab in Treating Women With…
NCT00054587 · UNICANCER, Other · Completed
Key facts
| NCT number | NCT00054587 |
|---|---|
| Title | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer |
| Official title | Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And… |
| Lead sponsor | UNICANCER, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | Trastuzumab, Cyclophosphamide, docetaxel, Epirubicin, Fluorouracil |
| Enrollment | 3,010 |
| Start date | Jun 1, 2001 |
| Primary completion | Jun 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 19, 2013 |
| Countries | France |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: